Radius Health
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 2.1b | 1.7b | 2.8b | 3.5b | 2.9b | 2.7b | 2.8b |
% growth | (10 %) | (20 %) | 61 % | 26 % | (17 %) | (8 %) | 3 % |
EBITDA | 138m | 21.5m | 214m | 227m | 38.3m | - | - |
% EBITDA margin | 6 % | 1 % | 8 % | 7 % | 1 % | - | - |
Profit | 56.3m | (4.1m) | 165m | 169m | (25.8m) | - | - |
% profit margin | 3 % | - | 6 % | 5 % | (1 %) | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$15.0m | Series C | ||
$66.0m | Series C | ||
$21.4m | Growth Equity VC | ||
$43.0m | Growth Equity VC | ||
N/A | $52.0m | IPO | |
N/A | Late VC | ||
N/A | $345m | Post IPO Equity | |
N/A | $300m | Post IPO Debt | |
N/A | $175m | Post IPO Debt | |
* | $890m Valuation: $890m 0.3x EV/LTM Revenues 4.2x EV/LTM EBITDA | Buyout | |
Total Funding | €194m |
Recent News about Radius Health
EditRadius Health, Inc. is a fully integrated biopharmaceutical company focused on developing and commercializing innovative endocrine therapeutics. The company primarily serves patients suffering from osteoporosis and breast cancer, aiming to address significant unmet medical needs in these areas. Operating in the healthcare and pharmaceutical markets, Radius Health employs a business model that spans from drug discovery and development to commercialization. Revenue is generated through the sale of its FDA-approved products, as well as through strategic partnerships and collaborations with other pharmaceutical companies. The company's flagship product, abaloparatide, is a treatment for osteoporosis, and it continues to advance its pipeline with new therapeutic candidates. Radius Health is committed to scientific excellence and improving patient outcomes through its innovative therapies.
Keywords: biopharmaceutical, endocrine therapeutics, osteoporosis, breast cancer, drug discovery, commercialization, abaloparatide, FDA-approved, patient outcomes, strategic partnerships.